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Introduction
Liver transplantation (LT) currently remains the only long-
term treatment option for patients with end-stage liver failure. 
The success of LT was enabled by the introduction of effective 
pharmacological immunosuppressive strategies, which mostly 
target recipient T lymphocyte responses. The drugs that mediate 
immunosuppression (IS) in LT recipients exert their effects 
either by inhibiting intracellular T lymphocyte signalling or 
cellular proliferation. Calcineurin inhibitors (CNIs)1 and 
mammalian target of rapamycin inhibitors (mTOR-I)2 target the 
former, whereas corticosteroids3 or antimetabolites like mycophe-
nolate mofetil4 or azathioprine5 impair the latter. Moreover, bio-
logic agents blocking the anti-interleukin 2 receptor on activated 
T lymphocytes (e.g., basiliximab6) or inhibiting T lymphocyte 
costimulation (preliminary data in kidney transplantation: 
belatacept7) have been developed more recently to reduce CNI 
exposure.
While providing effective protection against acute and chronic 
cellular rejection of the allograft, lifelong IS, particularly 
corticosteroids and CNIs, are known to cause significant side 
effects8. Common side effects include various malignancies, 
cardiovascular and metabolic diseases, renal toxicity, as well 
as susceptibility to infections9–14. These significant side 
effects account for chronic morbidity and impair quality of life 
of LT recipients. Therefore, efforts to minimise exposure to 
immunosuppressive drugs while preserving graft integrity are 
warranted.
Among all solid organ transplants (SOT), the transplanted 
liver exhibits unique immunoregulatory properties, which 
render liver allografts less dependent on IS15–17. The attrib-
uted mechanisms of liver allograft tolerance are complex and 
may include deficient antigen presentation, large antigen load, 
neutralisation of alloantibodies, regulatory T cell (Treg) genera-
tion, and long-term microchimerism18–22. Accordingly, LT recipi-
ents usually require less intensive IS treatment with lower levels 
and/or numbers of immunosuppressive drugs compared to 
other SOT recipients23. In addition, human leukocyte antigen 
(HLA) match requirements between donor and recipient are less 
stringent, and the incidence and severity of acute cellular 
rejection (ACR) episodes are lower and usually better tolerated in 
LT as compared to other SOT recipients24.
Based on these particular features, clinical studies that examined 
IS minimization or even complete IS withdrawal (ISW) in LT 
recipients have been initiated already in the 1990s25–28. Most 
of these ISW studies (at least all of the recent ones) applied 
predefined eligibility criteria such as absence of recent rejec-
tion episodes or absence of significant histological lesions in 
a baseline biopsy29,30. In all studies, a significant subset of study 
participants exhibited stable allograft function and histologi-
cal graft integrity despite complete ISW31. In agreement with the 
nomenclature used in the literature, we herein call this state of 
spontaneous immunological transplant tolerance operational 
tolerance (OT)32. However, the majority of study participants 
still would experience an ACR episode or develop abnormal 
liver function tests following ISW and eventually require the 
reinstitution of immunosuppressive drugs31 (ISW failure). The 
mechanisms underlying ISW success or failure in LT recipients 
are currently not completely elucidated. Likewise, whether ISW 
outcomes may be predictable at all (see below) or IS minimisation 
is a safer alternative to complete ISW is not yet known33.
The discovery of OT has promoted extensive research activity 
over the last two decades34. On the one hand, it is important to 
explore the factors that are associated with or enable the 
development of OT in a subset of transplant recipients35. More 
detailed knowledge on such predictors of spontaneous OT 
will help to refine the eligibility criteria for LT recipients to 
participate in ISW trials and hopefully increase the fraction of 
successful ISW attempts. On the other hand, researchers have 
started to address the question as to whether OT can be induced 
by immune manipulation prior to ISW. Thus, infusion of 
donor-derived hematopoietic stem cells36–40, Treg41, regulatory 
dendritic cells (DCreg)42 or mesenchymal stem cells43,44, as 
well as lymphodepletion protocols using T lymphocyte-directed 
antibodies45 have been or are being tested for their potential to 
induce tolerance31.
Why it is important to do this review?
Regarding the therapeutic dilemma of deleterious effects of 
chronic IS vs. the risk of ISW failure and graft injury after 
LT, there is a medical need to define clinical and biochemical 
markers to predict the success of ISW. Up to now, there is only 
one systematic review that addressed the benefits and harms of 
ISW in LT recipients46. It focused on CNI and included only 
randomized controlled trials (RCTs) comparing ISW and IS 
continuation after LT. The authors identified a single ongoing 
RCT, which has been published in the meantime47. In this RCT, 
the non-inferiority analysis of ISW vs. unchanged IS mainte-
nance treatment on a composite morbidity/mortality endpoint 
was inconclusive. Based on these results and an unpublished 
scoping search in the literature that did not identify any new 
RCTs on this comparison, we concluded that there was not 
enough data for a new systematic review approach comparing 
ISW and IS continuation after LT.
In contrast, the number of publications that highlight 
predisposing factors or biomarkers for spontaneous OT in 
ISW cohorts is increasing35. We, therefore, reasoned that the 
systematic scoping for evidence on such factors would best 
inform the community regarding the therapeutic dilemma of IS 
after LT. Accordingly, this scoping review will for the first time 
systematically collect biomarkers and clinical parameters that 
are likely predictors of spontaneous OT. The anticipated results 
shall set the basis for subsequent evidence syntheses or 
clinical trials with a sharpened research focus. Any evidence 
            Amendments from Version 1
In version 2, we aimed to clarify three issues:
i) The scoping review will include paediatric and adult patients
ii) The scoping review will focus on studies on full IS withdrawal 
and exclude studies on IS minimisation
iii) The primary objective of the scoping review will be to map all 
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that will help understand the spontaneous development of OT 
and increase the fraction of successful ISW by enabling an 
informed preselection of ISW candidates is of great value to the 
community, as it will provide valuable guidance in the therapeutic 
dilemma of IS after LT.
Study aim and objectives/questions
The objective of this scoping review will be to map all published 
prognostic factors for spontaneous OT in non-viral hepatitis and 
non-autoimmune disease LT recipients who are undergoing ISW. 
The obtained results may inform the subsequent conduct of a 
systematic review with a more targeted review question.
Specifically, the review questions are:
i)       What are clinical parameters and biomarkers that predis-
pose LT recipient ISW candidates to achieve spontaneous 
OT?
ii)      What are the success rates of ISW and achievement of 
spontaneous OT in LT recipients?






The primary eligibility criterion will be the assessment of 
spontaneous OT, i.e. rejection-free liver allograft survival for at 
least one year following ISW. LT recipients of any age or stage 
will be included, but recipients with underlying autoimmune 
diseases, replicative viral disease and/or multi-organ recipients 
will be excluded. Studies reporting on mixed populations will 
be included, if less than 20% of the study population has a 
viral or autoimmune liver disease aetiology. Studies that do 
not report the liver disease aetiologies for LT in their popula-
tion will also be included. All pharmacological IS regimens 
including combination treatments being completely withdrawn 
will be eligible. However, studies addressing dose reduction 
of IS including IS minimisation, withdrawal of a subset of 
drugs from IS combination treatments (e.g. withdrawal of 
corticosteroids in patients on CNI maintenance treatment), 
or conversion between IS regimens (e.g. CNI to mTOR-I 
conversion vs. CNI continuation) will be excluded.
We will include studies that assess an association of pre-ISW 
clinical parameters or biomarkers on the development of OT. 
Studies exclusively addressing the effectiveness of induction 
or immunomodulation therapies for development of OT (using 
lymphodepletion or infusion with regulatory immune cells) 
will be excluded. Prespecified pre-ISW clinical parameters 
potentially predicting OT are sex, recipient age at LT, time 
since LT, history of episodes of rejection, liver histology, 
pharmacologic IS regimen, living (LD) or deceased donor (DD) 
LT, degree of kinship (or HLA match) of the donor, lymphocy-
totoxic crossmatch, liver disease aetiology, and previous preg-
nancies, SOT, or blood transfusions. Prespecified pre-ISW 
biomarkers potentially predicting OT are any up- or downregu-
lated immune cell subsets (detected by flow cytometry or mass 
cytometry), any up- or downregulated genes or micro RNAs 
in the liver allograft or peripheral blood (detected by gene 
microarray, quantitative PCR, or RNA-seq), epigenetic markers, 
and anti-HLA antibodies (detected by ELISA, single antigen 
bead assay, or complement-dependent cytotoxicity assay). Owing 
to the risk of confounding by interrupted IS in the OT cohort 
(i.e. featuring successful ISW), data on post-ISW biomarkers 
will be excluded unless the same biomarkers were measured in 
the same patients already before ISW.
Types of study to be included
We will include prospective, retrospective, randomised, and 
non-randomised studies irrespective of publication status and 
including case-control and cross-sectional designs. By reporting 
on those patients that did not achieve OT after ISW most relevant 
studies would include a “control cohort” by default. Principal 
investigators of ongoing studies and conference abstracts 
will be contacted twice by email for the sharing of their data. 
Conference abstracts where the data was subsequently published 
in a peer-reviewed article will be excluded. Animal studies, case 
reports, case series (i.e. publications where patient histories of 
exclusively tolerant or non-tolerant ISW-liver recipients are 
reported48), reviews, letters, and editorials will be excluded. No 
language or publication date restrictions will be applied.
Identification of relevant literature. An information specialist 
(CA-H) will develop the search strategies, which will be reviewed 
by a second information specialist. Database-specific subject 
headings and text words (synonyms and word variations) for 
liver transplantation, ISW, and OT, graft survival, or liver biopsy 
will be used. We will search the electronic databases Embase via 
Elsevier, Medline via Ovid, and the Cochrane Central Register 
of Controlled Trials (CENTRAL). The search string for Embase 
is provided in Box 1. We will also search the study registry 
clinicaltrials.gov as well as the World Health Organization’s 
International Clinical Trials Registry Platform (ICTRP) for 
ongoing studies. All retrieved references will be exported to 
EndNote X9 and deduplicated.
One reviewer (CA-H) will screen the deduplicated references 
based on their titles and abstracts. All potentially relevant 
references will be retrieved in full-text and independently 
assessed by two reviewers (CA-H, JV). Any disagreements over 
eligibility will be resolved by consensus. Where necessary, 
a third review author (SH) will make a final judgement. All 
judgements at the full-text screening stage will be collected in a 
standardised MS Excel 2016 form. Articles in foreign languages 
that none of the review authors is familiar with will be checked 
for eligibility by other researchers before translation will be 
considered. Potentially relevant ongoing studies and conference 
abstracts will only be included if principal investigators will 
provide us with chartable data that relate to our primary 
outcomes (see below).
To identify possible additional studies that will escape our 
electronic database searches, we will screen the bibliographic 
references and the citations of all included articles that are 
indexed in Scopus or the Web of Science.
Data analysis
Quality appraisal. Within the framework of this scoping review, 
no quality appraisal is planned.
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Box 1. Search strategy for Embase
(‘liver transplantation’/exp OR (OLT OR LTx):ab,ti OR ((‘liver’/de OR ‘liver lobe’/exp OR ‘liver disease’/exp OR ‘obstructive bile duct 
disease’/exp OR ‘bile duct atresia’/de OR (liver OR hepatic OR hepato* OR hepatis OR hepatitis OR intrahepatic OR extrahepatic OR 
cirrhosis OR cirrhotic OR ‘periportal fibrosis’ OR jaundice OR icterus OR bilirubinaemia OR cholestasis OR cholestatic OR ((bile OR biliary 
OR choledoch*) NEAR/3 (obstruction OR stasis OR occlusion OR stenosis OR stricture OR obliteration OR atresia OR agenesi*))):ab,ti) 
AND (‘transplantation’/de OR ‘organ transplantation’/de OR ‘allotransplantation’/de OR ‘orthotopic transplantation’/de OR ‘recipient’/exp OR 
(transplant* OR Tx OR allotransplant* OR graft* OR allograft* OR recipient*):ab,ti)))
AND
(((‘immunosuppressive agent’/exp OR ‘calcineurin inhibitor’/exp OR ‘mammalian target of rapamycin inhibitor’/de OR ‘immunosuppressive 
treatment’/de) AND (‘treatment withdrawal’/exp OR ‘weaning’/de)) OR ((((immunosuppress* OR immuno-suppress* OR immune-suppress* 
OR immunodepress* OR immuno-depress* OR immune-depress* OR anti-rejection OR antirejection OR ‘immune system-suppressing’ 
OR ‘transplantation reaction inhibition’ OR anti-metaboli* OR antimetaboli* OR azathioprine OR belatacept OR cyclophosphamide OR 
daclizumab OR ‘mycophenolate mofetil’ OR MMF OR ‘mycophenolic acid’ OR cellcept OR ‘calcineurin inhibitor*’ OR ‘protein phosphatase 
2B inhibitor*’ OR cyclosporin* OR ciclosporin* OR neoral OR sandim* OR tacrolimus OR advagraf OR prograf* OR fk506 OR fk-506 OR 
‘mammalian target of rapamycin inhibitor*’ OR ‘mammalian target of rapamycin kinase inhibitor*’ OR ‘mechanistic target of rapamycin 
inhibitor*’ OR ‘mechanistic target of rapamycin kinase inhibitor*’ OR ‘mTOR inhibitor*’ OR ‘mTOR kinase inhibitor*’ OR everolimus 
OR rad001* OR rad-001* OR rapamune OR rapamycin OR sirolimus) NEAR/4 (withdraw* OR taper* OR wean* OR minimization OR 
minimisation OR minimizing OR minimising OR sparing OR eliminat* OR reduction OR reducing OR lower* OR cessation OR discontinu* 
OR interrupt* OR abstinence OR avoid* OR stop* OR downgrad* OR diminish* OR free*)) OR is-withdraw* OR is-taper* OR is-wean* OR 
is-minimization OR is-minimisation OR is-minimizing OR is-minimising OR is-sparing OR is-eliminat* OR is-reduction OR is-reducing OR 
is-lower* OR is-cessation OR is-discontinu* OR is-interrupt* OR is-abstinence OR is-avoid* OR is-stop* OR is-downgrad* OR is-diminish* 
OR is-free):ab,ti))
AND
(‘transplantation tolerance’/de OR ‘immunological tolerance’/de OR ‘immunoregulation’/de OR ‘immunoreactivity’/de OR ‘graft survival’/de 
OR ‘liver biopsy’/de OR (tolerogen* OR ‘tolerant patient*’ OR ‘tolerant state’ OR ‘state of tolerance’ OR ‘sustained weaning’ OR ((transplant* 
OR posttransplant* OR operational* OR immune OR immunologic* OR alloimmune OR allograft* OR graft* OR alloantigen* OR antigen* 
OR chimerism OR donor-specific OR peripheral) NEAR/3 (tolerance OR tolerant OR tolerated OR tolerating OR acceptance OR protect* 
OR quiescen* OR unresponsive* OR nonresponsive* OR un-responsive* OR non-responsive*)) OR immunoregulat* OR immunosurveill* 
OR immunoreactiv* OR immunoactiv* OR ((immune OR immunologic*) NEXT (regulat* OR surveill* OR reactiv* OR activ*)) OR ((graft 
OR allograft OR transplant* OR liver OR hepatic) NEAR/3 (survival OR health OR function OR ‘resistance to rejection’)) OR ((inhibit* OR 
decrease OR abolish OR suppress* OR reduc* OR ameliorat* OR improve* OR absent OR avoid* OR prevent*) NEAR/3 (graft OR allograft 
OR transplant* OR liver OR hepatic) NEAR/3 (injury OR complication* OR dysfunction OR inflammation OR fibrosis OR infiltration)) OR 
((inhibit* OR decrease OR abolish OR suppress* OR reduc* OR ameliorat* OR improve* OR absent OR avoid* OR prevent*) NEAR/3 
(rejection OR ‘immune response*’ OR ‘alloimmune response*’ OR ‘T-cell response*’ OR ‘B-cell response*’ OR ‘antibody response*’ OR 
‘humoral response*’)) OR ((liver OR hepatic) NEAR/3 (biopsy OR biopsies OR puncture*))):ab,ti)
NOT
((‘animal’/de OR ‘animal experiment’/exp OR ‘nonhuman’/de) NOT (‘human’/exp OR ‘human experiment’/de))
NOTE: The subject heading “graft rejection” (and respective free text terms) was omitted from the third search block, because its 
tentative inclusion resulted in a non-manageable increase of hits.
Data charting. Next to reported prognostic and non-prognostic 
factors (clinical parameters and biomarkers) for OT, which will 
be the primary outcomes, we will also chart the percentage of 
successful ISW and achievement of sustained OT and the rate 
of graft loss in each trial as the secondary outcomes. Two reviewers 
(CA-H, JV) will independently chart the data from each 
eligible article using a jointly developed MS Excel 2016 
charting form that will be pilot tested using four eligible full-
text articles. If necessary, the charting form will be updated in 
an iterative process. Any disagreements will be solved by 
discussion. Data will be sought for the following variables:
•     Article characteristics such as first author, year of publica-
tion, country of origin, and bibliographic details
•     Funder
•     Trial ID
•     Mono- or multicenter study
•     Study design, IS maintenance control group yes/no
•     DD and/or LD LT
•     Recipient age at LT
•     Donor age
•     Liver disease aetiology
•     Time from LT to ISW
•     Duration of follow-up
•     IS drug(s)
•     ISW schedule
•     Method(s) for assessing OT
•     Total number of patients that are included in the prognostic 
analyses
•     Percentage of successful ISW (achievement of OT)
•     Percentage of graft loss
•     Biomarkers predicting OT
•     Clinical parameters predicting OT
•     Numerical evidence for positive associations
•     Biomarkers explicitly not predicting OT
•     Clinical parameters explicitly not predicting OT
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Strategy for data synthesis and presentation. For each included 
article, ongoing study, or conference abstract with data, we will 
present the charted data in a “results of individual sources 
of evidence” table. For the synthesis of collated prognostic 
factors (biomarkers and clinical parameters) for OT, we will 
use descriptive statistics showing the individual sources of 
evidence that support each factor. In addition to a tabular view, 
the results will be narratively synthesized in the review text. 
Together, these results will provide a comprehensive scope of 
past research activity on this topic and likely identify promising 
future research avenues.
Design and reporting guidelines
This scoping review will be conducted along with the guide-
lines by the Joanna Briggs Institute49 and reported according 
to the “Preferred Reporting Items for Systematic reviews and 
Meta-Analyses extension for Scoping Reviews” (PRISMA-ScR) 
statement50.
Dissemination of results
The completed review will be published in a peer-reviewed 
journal.
Study status
Start date of search: July 2019; anticipated completion date of 
review: May 2020.
Current study status: preliminary searches, yes; piloting of the 
study selection process, yes; formal screening of search results 
against eligibility criteria, started; data extraction, no; data 
analysis, no.
Conclusions
Since the first reports of spontaneous OT in LT25–28, numerous 
studies of ISW have been published (reviewed in 32). These 
studies were initially uncontrolled and heterogeneous in their 
design, rendering any comparison between them and any 
conclusions difficult to draw. Following the creation of inter-
national consortia (Immune Tolerance Network – ITN – in the 
US and Reprogramming the Immune System for the Establish-
ment of Tolerance – RISET – in Europe), inclusion/exclusion 
criteria of ISW studies in LT have been harmonised, thus 
allowing cross-comparisons and cross-validations between 
studies. For instance, two ongoing multicenter trials (LIFT51 and 
OPTIMAL52) share the same inclusion/exclusion criteria.
These ISW trials have in parallel fuelled the need to find reliable 
biomarkers for the identification of those patients who are more 
likely to successfully stop IS, a problem that is most critical for 
the safety and future applicability of ISW. While clinically not 
available yet, several biomarkers have already been evaluated 
in LT recipients. In this scoping review, we will map all informa-
tion on this body of literature. In addition to that, our searches 
in clinical trial registries will provide an overview of the 
current research activity in the field. The anticipated results 
will allow us to determine possible research gaps and whether 
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